Moreover, the prognostic signature based on ITGB1, ITGB4, ITGB5 and ITGB6 may facilitate clinicians to identify more aggressive and immunosuppressive tumours and make more individually appropriate therapeutic decisions. The gene discussed is ITGB4; the disease is neoplasm.